T he management of inflammatory bowel disease (IBD) is today increasingly based on the objective assessment of mucosal integrity and tissue inflammation. 1 Classically, clinical activity has guided the monitoring of patients with IBD. However, symptoms may underestimate endoscopic activity in up to 30% of patients with ulcerative colitis (UC). 2 Moreover, C-reactive protein (CRP) often has a negligible response on disease activity in UC, especially in mild and moderate cases. 3, 4 It has been demonstrated that the improvement of the mucosa indicates a better outcome of the disease, [5] [6] [7] both in UC and in Crohn's disease (CD). However, direct evaluation of the mucosa requires the performance of an endoscopy, which is invasive, time consuming, expensive, and does not always reach the affected segment of the intestine. Therefore, surrogate markers of intestinal inflammation would be of great value to the clinician for monitoring inflammatory disease activity and for measuring the effects of treatment. Fecal calprotectin (FC) represents 60% of cytosolic proteins in granulocytes. The presence of FC in feces is therefore proportional to neutrophil migration to the gastrointestinal tract and to the degree of inflammation.
The role of several biomarkers in assessing endoscopic activity in IBD has been recently reviewed by Lewis. 8 Among these biomarkers, FC showed the best correlation with endoscopic activity in both CD and UC. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In addition, 2 meta-analyses demonstrated the value of FC in discriminating IBD from non-IBD diagnoses. 20, 21 However, only 2 studies have assessed the accuracy of FC in predicting mucosal healing (MH) in UC. 19, 22 Moreover, there are still scarce data about 2 relevant points affecting the use of FC in clinical practice: the optimal thresholds of FC for the prediction of endoscopic activity and the reliability of the rapid point-of-care tests compared with the enzyme-linked immunosorbent assay (ELISA) test in patients with IBD.
Regarding the cutoff levels of FC, different threshold concentrations ranging from 50, 10, 22 100, 19 and to 250 mg/g 23 have been proposed in the literature. However, there is still no agreement on what cutoff level of FC should be considered for predicting endoscopic activity.
The ELISA test has been the most widely used technique for measuring FC. This technique, though highly reliable, presents several drawbacks: the fact that it is time consuming (up to 4-hour duration), the need to collect multiple samples to make the running test more cost effective, and the availability of a laboratory and trained personnel to perform the test. To overcome these limitations, 2 kinds of point-of-care tests have been developed: semi-quantitative ones that provide a range of FC levels and a rapid quantitative (QPOCT), which is as fast as the semiquantitative tests but provides an exact number as the ELISA test. Previous studies [24] [25] [26] [27] using QPOCT observed a good correlation with the ELISA test but none of them explored its ability to predict endoscopic activity in IBD population.
The aims of our study were to evaluate the accuracy of FC and to determine the optimal cutoff levels for the prediction of endoscopic activity. We have also studied the reliability of the rapid quantitative test for the determination of FC compared with the previously used ELISA test.
MATERIALS AND METHODS

Participants
One hundred and twenty-three adult patients with previous known UC referred for colonoscopy to the Department of Gastroenterology of Bellvitge University Hospital (Hospitalet de Llobregat, Barcelona) between December 2010 and February 2012 were prospectively and consecutively included in the study. Nineteen of the 123 patients were referred twice for endoscopic study and 2 of them a third time during this period, so 146 colonoscopies and/or rectosigmoidoscopies were performed. Inclusion criteria included appropriated diagnosis for UC (with endoscopy, biopsies, and/or image) at least within the 3 previous months of the study and age between 18 and 85 years. Exclusion criteria included pregnancy, nonsteroidal anti-inflammatory drugs intake, concomitant gastrointestinal infection, surgery within the past 3 months, colorectal cancer, predominant perianal symptoms, and CD or indeterminate colitis diagnosis.
Study Design
Patients were visited in our IBD unit previous to their colonoscopy to invite them to participate in the study, provide them with the recipient for FC collection, perform a clinical interview, and carry out blood tests. If diarrhea was present, we also performed a microbiological study of feces consisting of conventional culture, parasites, and Clostridium difficile detection to exclude gastrointestinal infection. At our center, the diagnosis of C. difficile consists of 2 techniques: toxin detection in fecal samples using cell cytotoxicity neutralization assay and anaerobic culture followed by toxin detection (i.e., toxigenic culture). Samples for microbiological analysis were processed in the Microbiology Department and fecal samples for FC were collected in the Endoscopy Department and stored at 2208C until analysis.
Clinical Activity
Clinical activity was assessed according to the clinical criteria of the Mayo score. Symptomatic remission was based on the patient-rated Mayo subscores of stool frequency (0 points, normal number for the patient; 1 point, 1-2 stools more than normal; 2 points, 3-4 stools more than normal; and 3 points, $5 stools more than normal) and rectal bleeding (0 points, no blood seen; 1 point, streaks of blood with stool less than half the time; 2 points, obvious blood with stool most of the time; and 3 points, blood alone passes). Symptomatic remission was defined as a Mayo stool frequency subscore of 0 or 1 and a Mayo rectal bleeding subscore of 0. 7 
Serological Biomarkers
Blood tests included leukocytes (lower range 3.9 g/L), platelets (lower range 150.0 g/L), erythrocyte sedimentation rate, and CRP (upper limit of normal , 5 mg/L).
Endoscopic Disease Activity
One hundred and forty-six colonoscopies were performed of which 108 were complete to cecum and 38 were rectosigmoidoscopies. Rectosigmoidoscopies were performed instead of colonoscopies in a flare context to avoid iatrogenic damage or in cases of distal UC when total affected mucosa was evaluated and normal mucosa was reached. Two trained endoscopists (F.R.-M. and J.G. C.) from our unit, who were blind for the other variables from the study, carried out the colonoscopies. Endoscopic activity was assessed according to the Mayo endoscopic subscore. "Endoscopic remission" was defined as Mayo endoscopic subscore grade #1, and "no endoscopic activity" was defined as Mayo endoscopic subscore grade 0. "Endoscopic activity" was defined as Mayo endoscopic subscore grade $2, and "any degree of endoscopic activity" was defined as Mayo endoscopic subscore grade $1. Extension of disease activity was reported according to the Montreal classification (proctitis, left-sided colitis, or extensive colitis) when any degree of endoscopic activity was observed.
FC Determination
Stool sample collection was performed within 1 to 3 days before endoscopy and bowel preparation. All samples were stored at 2208C, thawed, and analyzed by an ELISA test (Calprotectin Bühlmann ELISA; Bühlmann, Schonenbuch, Switzerland) and by a QPOCT (Quantum Blue; Bühlmann). The quantitative point-ofcare test (FC-QPOCT) relies on the lateral flow assay technology including an easy to use reader system allowing for a quantitative read out. There are 2 kinds of FC-QPOCT: the lower range Quantum Blue (LF-CAL) and the high range Quantum Blue (LF-CHR), which provide quantitative results within minutes, ranging from 30 to 300 mg/g or 100 to 1800 mg/g FC, respectively. The range of the ELISA test (FC-ELISA) is 10 to 1800 mg/g. The median time analysis required for FC-ELISA is 2 hours for 88 samples and 12 to 15 minutes for each sample with FC-QPOCT depending on the kit (12 minutes for LF-CAL and 15 minutes for LF-CHR). The sample amount needed is 50 to 150 mL and 80 mL for FC-QPOCT. Sensitivity of both tests is ,10 mg/g. FC measurements were taken by 3 gastroenterologists and the IBD nurse (T.L.O., A.L.G., L.R.-A., and E.S.P.) who were blind for endoscopic activity and other variables, following appropriate training. We started the study using the LF-CAL kit and changed to the LF-CHR kit when available. All samples scoring .300 mg/g with the LF-CAL were performed again with the LF-CHR kit to obtain their exact value.
Statistical Analysis
The statistical analysis was carried out using the SPSS version 19.0 statistical package (SPSS, Inc., Chicago, IL). Numerical results were given as the mean 6 standard deviation and range, except when specified. Student's T test, Mann-Whitney U test, and analysis of variance factor were used to compare means. Qualitative results were based on the chi-square test. The correlation analysis between FC, endoscopic activity, and other biomarkers was based on Spearman's correlation coefficient rank (r). Multivariate analysis consisted of multiple logistic regression. Accuracy analysis included receiver operator characteristic curve analyses with its 95% confidence intervals and test characteristics, such as sensitivity, specificity, positive and negative predictive values, and overall accuracy. Statistical significance was accepted for P , 0.05. Correlation between FC-ELISA and FC-QPOCT was analyzed by Spearman's correlation coefficient rank and interclass correlation index.
Ethical Considerations
This study was approved by the ethics committee of Bellvitge University Hospital and all patients gave their informed written consent for participation.
RESULTS
A total of 146 endoscopies were performed on 123 patients with UC between December 2010 and February 2012. Epidemiological, clinical, biological, and endoscopic characteristics of patients are shown in Table 1 .
Correlation Between Both Techniques
Spearman's correlation coefficient rank between FC-QPOCT and FC-ELISA was 0.911 (P , 0.001). The interclass correlation index was 0.904 (95% confidence interval, 0.864-0.932; P , 0.001). Results are shown in Figure 1 .
Relation of FC with Endoscopic Activity, Clinical, and Serological Markers FC determined by QPOCT and ELISA presented a correlation with endoscopic activity of 0.727 and 0.741, respectively (Spearman's correlation coefficient rank; P , 0.001 in both cases).
FC-QPOCT discriminated "endoscopic activity" defined as Mayo endoscopic subscore $2 from "endoscopic remission" defined as Mayo endoscopic subscore #1 (mean levels of 1368.39 6 618.18 mg/g and 294.91 6 456.36 mg/g, respectively, P , 0.001). FC-ELISA showed similar results (mean levels of 1299.49 6 608.17 mg/g and 246.37 6 357.73 mg/g, respectively, P , 0.001). Median levels of FC-ELISA and FC-QPOCT for each endoscopic Mayo grade are shown in Figure 2 .
Correlations between Mayo endoscopic subscore, FC (FC-ELISA and FC-QPOCT), clinical activity, and the serological variables are shown in Table 2 . The Mayo endoscopic subscore correlated more closely with FC-QPOCT (Spearman's correlation coefficient rank r ¼ 0.727, P , 0.001) followed by clinical activity (r ¼ 0.636, P , 0.001), platelets (r ¼ 0.381, P , 0.001), leucocytes (r ¼ 0.300, P ¼ 0.001), and CRP (r ¼ 0.291, P ¼ 0.002). Similar results were obtained with FC-ELISA. In the multivariate analysis, FC-QPOCT and clinical assessment were both independent predictors of endoscopic activity (Table 3) . Similar results were obtained with FC-ELISA (data not shown).
Accuracy of FC for the Prediction of Mayo Endoscopic Subscore £1
The prediction of "endoscopic remission" defined as Mayo endoscopic subscore #1 with FC-QPOCT and FC-ELISA presented an area under the curve of 0.906 and 0.924, respectively (Fig. 3) . A 250 mg/g cutoff level of FC-ELISA (n ¼ 146) had a sensitivity of 73.5%, a specificity of 89.7%, a negative predictive value of 79.5%, and a positive predictive value of 86.2% (global accuracy 82.2%). A 280 mg/g cutoff level FC-QPOCT (n ¼ 121) had a sensitivity of 75.4%, a specificity of 89.1%, a negative predictive value of 80.3%, and a positive predictive value of 86% (global accuracy 82.7%). Results are shown in Table 4 .
Accuracy of FC for the Prediction of Mayo Endoscopic Subscore 0
The prediction of "no endoscopic activity" defined as Mayo endoscopic subscore grade 0 with FC-QPOCT and FC-ELISA presented an area under the curve of 0.864 and 0.843, respectively (Fig. 3) .
A 160 mg/g cutoff level had a sensitivity of 64.9% and a specificity of 83.9% with FC-QPOCT and a sensitivity of 66.7% and a specificity of 84.5% with FC-ELISA. Results shown in Table 5 .
Among the asymptomatic patients (n ¼ 72), 30.6% (n ¼ 22) presented endoscopic activity. FC would have classified them correctly because 81.8% (18 out of 22) had an FC equal or superior to 280 mg/g. Given that both FC and clinical activity are independently related to endoscopic activity, we created a score to predict "endoscopic remission" including both variables. When we combined clinical activity and FC-QPOCT with a 280 mg/g cutoff level, specificity improved to 93.8% (from 67.9% using only clinical activity), whereas sensitivity decreased to 70.2% (from 88.2% using only clinical activity). Similar results were observed with FC-ELISA. An asymptomatic patient with a FC-QPOCT ,280 mg/g would have a 90.9% probability of having "endoscopic remission" (Table 4) .
Relation of FC Levels to Extension of UC
When considering only patients who underwent complete colonoscopy (intubation until cecum; n ¼ 108), we observed that FC-ELISA levels were related to the extension of endoscopic activity in our univariate analysis (F ¼ 23.11, P , 0.001). However, in the multivariate analysis, FC was not an independent predictor for extension of the disease when adjusting for endoscopic activity. Similar results were observed with FC-QPOCT (data not shown).
Correlation with Presence of Pseudopolyps
We found no relation between the presence of pseudopolyps and FC levels.
DISCUSSION
This study shows a significant correlation between FC levels and endoscopic activity in UC. Our results demonstrate that FC, with a 250 mg/g cutoff level for FC-ELISA or a 280 mg/g cutoff level for FC-QPOCT, is a more accurate marker of endoscopic activity than clinical activity and other frequently used biomarkers such as CRP. In the multivariate analysis, FC and clinical activity were independently related to endoscopic activity. Thus, the combination of both variables may be useful to exclude endoscopic activity in clinical practice. We found FC to be especially useful in asymptomatic patients. In line with Regueiro et al, 2 we observed that clinical assessment underestimated endoscopic activity in one third of our patients and that the use of FC would have classified them correctly in most cases (Table 4 ). This study is the first to use ELISA and a quantitative rapid test simultaneously for FC determination in patients with UC, and the correlation between both techniques was excellent (Fig. 1) . The use of the FC-QPOCT test provides a quantitative FC result within minutes, allowing fast and adequate decision-making.
Previous studies [5] [6] [7] have shown that MH is associated with a higher response to treatment, lower rates of relapse and hospitalization, and a reduced need for surgery. In addition, because chronic inflammation has been associated with an increased risk of colorectal cancer, MH would be protective in this context. 28 Reliable biomarkers of MH could avoid the need for endoscopic evaluation of the mucosa.
Among the biomarkers of endoscopic activity, FC has been put forward as one of the most promising for the management of patients with IBD. In patients with UC, FC has a particularly important role as a biomarker for endoscopic activity because of the negligible response of CRP and the underestimation of endoscopic activity by clinical assessment. However, previously published correlations between FC levels and endoscopic activity varied greatly depending on the study (correlations ranging from 0.51 to 0.83). This is probably because of the different endoscopic scores used in these studies: Mayo index, 7, 9, 12 Matt's index, 13 and Rachmilewitz index. 19 We decided to use the Mayo endoscopic subscore because it is the most common one, is easy to use, and has a demonstrated prognostic value. 7 In patients with UC, Mayo endoscopic subscore grade #1 has been used as a criterion for endoscopic remission. 7, 29, 30 In our study, FC proved to be an accurate biomarker of "endoscopic remission" (Mayo endoscopic subscore grade #1). FC also proved to be an accurate biomarker of "no endoscopic activity" (Mayo endoscopic subscore grade 0) to exclude any degree of endoscopic activity (Fig. 3) .
Current studies also provide controversial data regarding the cutoff level of FC for the prediction of endoscopic activity in UC. Cutoff levels vary depending on the technique used, the endoscopic 23 in a study involving 39 patients with UC and 87 patients with CD, found a 250 mg/g cutoff level to be the most accurate for predicting the presence of any mucosal inflammation in patients with UC defined by the Mayo endoscopic subscore $1 (a specificity of 100% and a sensitivity of 71%) and the presence of large ulcers in CD. In line with these results, we found a 250 and 280 mg/g cutoff levels for FC-ELISA and FC-QPOCT, respectively, to be the most accurate for predicting endoscopic remission as defined by the Mayo endoscopic subscore #1 (Table 4) . To maximize specificity for the diagnosis of endoscopic remission (Mayo endoscopic subscore #1), a 110 mg/g cutoff level would have a specificity of 100% and a sensitivity of 51.4%. In contrast, to maximize sensitivity, a cutoff level of 845 mg/g would have a sensitivity of 92.6% and a specificity of 74.4%. When using a more strict definition as "no endoscopic activity" (Mayo endoscopic subscore 0), the most accurate cutoff level was 160 mg/g for both techniques (Table 5 ). After the adjustment by endoscopic activity we found no relation between FC and the extension of the disease, which confirms the results of the study by Roseth et al. 9 We also explored the reliability of a rapid QPOCT against the FC-ELISA test, which is the only test used in the previous studies. The FC-ELISA test is an accurate technique that requires the availability of a laboratory and the collection of multiple samples. In contrast, the FC-QPOCT test is an easy and rapid technique that also provides quantitative results but that is more easily available and that can be performed individually. Unlike other rapid tests, the FC-QPOCT test provides a quantitative result that allows us to choose among different cutoff levels according to the clinical endpoint being considered.
Lastly, our study shows that the combination of clinical data and FC levels (both with FC-QPOCT or FC-ELISA) optimizes the utility of FC in clinical practice. Clinical remission and a FC-QPOCT ,280 mg/g (or FC-ELISA levels , 250 mg/g) almost excludes "endoscopic activity" defined as Mayo endoscopic subscore $2, whereas the presence of clinical activity and FC-QPOCT $280 mg/g (or FC-ELISA $ 250 mg/g) almost exclude "endoscopic remission" defined as Mayo endoscopic subscore #1 (Table 4) .
Our study has several limitations. First, because of the fact that this is the first study measuring FC levels with a rapid QPOCT in patients with UC, there is a need to validate our results externally. Second, this is a transversal study in which most of the patients with "endoscopic remission" were in long-lasting remission. One of the situations in which FC would be most useful is in evaluating response to treatment. However, there is a lack of a follow-up of FC levels in our patients with UC.
In conclusion, our results indicate that FC is a reliable surrogate marker of endoscopic activity in UC. Its accuracy in predicting endoscopic remission improves when using FC in combination with clinical data. This could be especially useful to confirm endoscopic remission in patients in symptomatic remission. Finally, the excellent correlation observed between the FC-ELISA test and the rapid quantitative test allows us to use FC more easily in our clinical practice. Therefore, it seems reasonable to incorporate FC in the management of patients with UC.
